Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66


PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials.

Orbai AM, Holland R, Leung YY, Tillett W, Goel N, Christensen R, McHugh N, Gossec L, de Wit M, Højgaard P, Coates LC, Mease PJ, Birt J, Fallon L, FitzGerald O, Ogdie A, Shea B, Strand V, Callis Duffin K, Tugwell P, Beaton D, Gladman DD.

J Rheumatol. 2018 Dec 15. pii: jrheum.181077. doi: 10.3899/jrheum.181077. [Epub ahead of print]


Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients.

Patrick MT, Stuart PE, Raja K, Gudjonsson JE, Tejasvi T, Yang J, Chandran V, Das S, Callis-Duffin K, Ellinghaus E, Enerbäck C, Esko T, Franke A, Kang HM, Krueger GG, Lim HW, Rahman P, Rosen CF, Weidinger S, Weichenthal M, Wen X, Voorhees JJ, Abecasis GR, Gladman DD, Nair RP, Elder JT, Tsoi LC.

Nat Commun. 2018 Oct 9;9(1):4178. doi: 10.1038/s41467-018-06672-6.


Are Your Patients Satisfied A Systematic Review of Treatment Satisfaction Measures in Psoriasis.

Salame N, Perez-Chada LM, Singh S, Callis Duffin K, Garg A, Gottlieb AB, Latella J, Merola JF, Armstrong AW.

Dermatology. 2018;234(5-6):157-165. doi: 10.1159/000490413. Epub 2018 Aug 17.


Identifying a Core Domain Set to Assess Psoriasis in Clinical Trials.

Callis Duffin K, Merola JF, Christensen R, Latella J, Garg A, Gottlieb AB, Armstrong AW.

JAMA Dermatol. 2018 Oct 1;154(10):1137-1144. doi: 10.1001/jamadermatol.2018.1165.


Proceedings of the 2017 GRAPPA Collaborative Research Network Meeting.

Jadon DR, Chandran V, Stober C, Ogdie A, Armstrong AW, Callis Duffin K, Gladman DD, Helliwell PS, O'Sullivan D, de Wit M, FitzGerald O, Ritchlin CT.

J Rheumatol Suppl. 2018 Jun;94:54-61. doi: 10.3899/jrheum.180141.


GRAPPA 2017 Project Report.

Callis Duffin K, FitzGerald O, Kavanaugh A, Mease PJ, Merola JF, Ogdie A, O'Sullivan D, Reddy SM, Ritchlin CT, Coates LC.

J Rheumatol Suppl. 2018 Jun;94:48-51. doi: 10.3899/jrheum.180139.


Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting.

Holland R, Tillett W, Ogdie A, Leung YY, Gladman DD, Callis Duffin K, Coates LC, Mease PJ, Eder L, Strand V, Elmamoun M, Højgaard P, Chau J, de Wit M, Goel N, Lindsay CA, FitzGerald O, Shea B, Beaton D, Orbai AM.

J Rheumatol Suppl. 2018 Jun;94:17-25. doi: 10.3899/jrheum.180142.


Efficacy and safety of ixekizumab in a randomized, double-blinded, placebo-controlled phase IIIb study of patients with moderate-to-severe genital psoriasis.

Ryan C, Menter A, Guenther L, Blauvelt A, Bissonnette R, Meeuwis K, Sullivan J, Cather JC, Yosipovitch G, Gottlieb AB, Merola JF, Callis Duffin K, Fretzin S, Osuntokun OO, Burge R, Naegeli AN, Yang FE, Lin CY, Todd K, Potts Bleakman A; IXORA-Q Study Group.

Br J Dermatol. 2018 Oct;179(4):844-852. doi: 10.1111/bjd.16736. Epub 2018 Jul 22.


Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis.

Coates LC, FitzGerald O, Merola JF, Smolen J, van Mens LJJ, Bertheussen H, Boehncke WH, Callis Duffin K, Campbell W, de Wit M, Gladman D, Gottlieb A, James J, Kavanaugh A, Kristensen LE, Kvien TK, Luger T, McHugh N, Mease P, Nash P, Ogdie A, Rosen CF, Strand V, Tillett W, Veale DJ, Helliwell PS.

Arthritis Rheumatol. 2018 Mar;70(3):345-355. doi: 10.1002/art.40391. Epub 2018 Feb 6.


Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling.

Dand N, Mucha S, Tsoi LC, Mahil SK, Stuart PE, Arnold A, Baurecht H, Burden AD, Callis Duffin K, Chandran V, Curtis CJ, Das S, Ellinghaus D, Ellinghaus E, Enerback C, Esko T, Gladman DD, Griffiths CEM, Gudjonsson JE, Hoffman P, Homuth G, Hüffmeier U, Krueger GG, Laudes M, Lee SH, Lieb W, Lim HW, Löhr S, Mrowietz U, Müller-Nurayid M, Nöthen M, Peters A, Rahman P, Reis A, Reynolds NJ, Rodriguez E, Schmidt CO, Spain SL, Strauch K, Tejasvi T, Voorhees JJ, Warren RB, Weichenthal M, Weidinger S, Zawistowski M, Nair RP, Capon F, Smith CH, Trembath RC, Abecasis GR, Elder JT, Franke A, Simpson MA, Barker JN.

Hum Mol Genet. 2017 Nov 1;26(21):4301-4313. doi: 10.1093/hmg/ddx328.


Clinical and pathologic factors associated with deep transection of biopsies of invasive melanoma.

Woodcock JL, Eyre ZW, Stoddard GJ, Callis Duffin K, Bowen AR.

J Am Acad Dermatol. 2017 Oct;77(4):766-768. doi: 10.1016/j.jaad.2017.04.1134. No abstract available.


National Psoriasis Foundation Priorities for Patient-Centered Research: Proceedings from the 2016 Conference.

Afifi L, Shankle L, Armstrong AW, Boas M, Bridges A, Chiguil V, Doris F, Callis Duffin K, Fielding E, Fleischmann R, Gelfand JM, Kiselica M, Kiselica C, LaFoy B, Latella JJ, Takeshita J, Truman S, Wan MT, Wilkerson V, Wu JJ, Siegel MP, Liao W.

J Psoriasis Psoriatic Arthritis. 2017 Summer;2(3):73-80.


Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study.

Strober B, Bagel J, Lebwohl M, Stein Gold L, Jackson JM, Chen R, Goncalves J, Levi E, Callis Duffin K.

J Drugs Dermatol. 2017 Aug 1;16(8):801-808.


International Dermatology Outcome Measures (IDEOM) Group 2016 New York Meeting: Meeting Summary and Data from the Psoriasis Working Group.

Perez-Chada LM, Singh S, Callis-Duffin K, Garg A, Gottlieb AB, Latella J, Armstrong AW, Merola JF.

J Drugs Dermatol. 2017 Aug 1;16(8):770-777.


Extension of ustekinumab maintenance dosing interval in moderate-to-severe psoriasis: results of a phase IIIb, randomized, double-blinded, active-controlled, multicentre study (PSTELLAR).

Blauvelt A, Ferris LK, Yamauchi PS, Qureshi A, Leonardi CL, Farahi K, Fakharzadeh S, Hsu MC, Li S, Chevrier M, Smith K, Goyal K, Chen Y, Muñoz-Elías EJ, Callis Duffin K.

Br J Dermatol. 2017 Dec;177(6):1552-1561. doi: 10.1111/bjd.15722. Epub 2017 Nov 16.


GRAPPA 2016 Project Report.

Helliwell PS, FitzGerald O, Coates LC, Callis Duffin K, Mease PJ.

J Rheumatol. 2017 May;44(5):706-710. doi: 10.3899/jrheum.170153.


Defining Outcome Measures for Psoriasis: The IDEOM Report from the GRAPPA 2016 Annual Meeting.

Callis Duffin K, Gottlieb AB, Merola JF, Latella J, Garg A, Armstrong AW.

J Rheumatol. 2017 May;44(5):701-702. doi: 10.3899/jrheum.170151.


Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group.

Ogdie A, de Wit M, Callis Duffin K, Campbell W, Chau J, Coates LC, Eder L, Elmamoun M, FitzGerald O, Gladman DD, Goel N, James J, Kalyoncu U, Latella J, Lindsay C, Mease PJ, O'Sullivan D, Steinkoenig I, Strand V, Tillett W, Orbai AM.

J Rheumatol. 2017 May;44(5):697-700. doi: 10.3899/jrheum.170150.


Proceedings of the GRAPPA 2016 Retreat.

Jadon DR, Gladman DD, Mease PJ, FitzGerald O, Chandran V, Goel N, Rosen CF, Maksymowych WP, Ritchlin CT, Ogdie A, Coates LC, Cauli A, Soriano ER, Husni ME, Campbell W, Azevedo VF, Callis Duffin K, Armstrong AW, Gottlieb AB, Kavanaugh A, Garg A, Helliwell PS.

J Rheumatol. 2017 May;44(5):668-673. doi: 10.3899/jrheum.170141.


Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016.

Orbai AM, de Wit M, Mease PJ, Callis Duffin K, Elmamoun M, Tillett W, Campbell W, FitzGerald O, Gladman DD, Goel N, Gossec L, Hoejgaard P, Leung YY, Lindsay C, Strand V, van der Heijde DM, Shea B, Christensen R, Coates L, Eder L, McHugh N, Kalyoncu U, Steinkoenig I, Ogdie A.

J Rheumatol. 2017 Oct;44(10):1522-1528. doi: 10.3899/jrheum.160904. Epub 2017 Feb 1. Erratum in: J Rheumatol. 2017 Apr;44(4):543.


From the Medical Board of the National Psoriasis Foundation: Treatment targets for plaque psoriasis.

Armstrong AW, Siegel MP, Bagel J, Boh EE, Buell M, Cooper KD, Callis Duffin K, Eichenfield LF, Garg A, Gelfand JM, Gottlieb AB, Koo JY, Korman NJ, Krueger GG, Lebwohl MG, Leonardi CL, Mandelin AM, Menter MA, Merola JF, Pariser DM, Prussick RB, Ryan C, Shah KN, Weinberg JM, Williams MO, Wu JJ, Yamauchi PS, Van Voorhees AS.

J Am Acad Dermatol. 2017 Feb;76(2):290-298. doi: 10.1016/j.jaad.2016.10.017. Epub 2016 Nov 28. Review.


Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience.

Callis Duffin K, Bukhalo M, Bobonich MA, Shrom D, Zhao F, Kershner JR, Gill A, Pangallo B, Shuler CL, Bagel J.

Med Devices (Auckl). 2016 Oct 12;9:361-369. eCollection 2016.


International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials.

Orbai AM, de Wit M, Mease P, Shea JA, Gossec L, Leung YY, Tillett W, Elmamoun M, Callis Duffin K, Campbell W, Christensen R, Coates L, Dures E, Eder L, FitzGerald O, Gladman D, Goel N, Grieb SD, Hewlett S, Hoejgaard P, Kalyoncu U, Lindsay C, McHugh N, Shea B, Steinkoenig I, Strand V, Ogdie A.

Ann Rheum Dis. 2017 Apr;76(4):673-680. doi: 10.1136/annrheumdis-2016-210242. Epub 2016 Sep 9.


Phase 3, open-label, randomized study of the pharmacokinetics, efficacy and safety of ixekizumab following subcutaneous administration using a prefilled syringe or an autoinjector in patients with moderate-to-severe plaque psoriasis (UNCOVER-A).

Callis Duffin K, Bagel J, Bukhalo M, Mercado Clement IJ, Choi SL, Zhao F, Gill A, Pangallo B, Shuler C, Mallbris L, Jackson K.

J Eur Acad Dermatol Venereol. 2017 Jan;31(1):107-113. doi: 10.1111/jdv.13768. Epub 2016 Aug 8.


Presidential Round Table: A Report from the GRAPPA Annual Meeting.

Gladman DD, Mease PJ, Boehncke WH, Helliwell PS, Callis Duffin K.

J Rheumatol. 2016 May;43(5):986-9. doi: 10.3899/jrheum.160120.


GRAPPA 2015 Research and Education Project Reports.

Mease PJ, Helliwell PS, Boehncke WH, Coates LC, FitzGerald O, Gladman DD, Deodhar AA, Callis Duffin K.

J Rheumatol. 2016 May;43(5):979-85. doi: 10.3899/jrheum.160119.


International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: An Update.

Merola JF, Armstrong AW, Saraiya A, Latella J, Garg A, Callis Duffin K, Gottlieb AB.

J Rheumatol. 2016 May;43(5):959-60. doi: 10.3899/jrheum.160114.


microRNAs in Psoriasis.

Hawkes JE, Nguyen GH, Fujita M, Florell SR, Callis Duffin K, Krueger GG, O'Connell RM.

J Invest Dermatol. 2016 Feb;136(2):365-371. doi: 10.1038/JID.2015.409. Review.


Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture.

Stuart PE, Nair RP, Tsoi LC, Tejasvi T, Das S, Kang HM, Ellinghaus E, Chandran V, Callis-Duffin K, Ike R, Li Y, Wen X, Enerbäck C, Gudjonsson JE, Kõks S, Kingo K, Esko T, Mrowietz U, Reis A, Wichmann HE, Gieger C, Hoffmann P, Nöthen MM, Winkelmann J, Kunz M, Moreta EG, Mease PJ, Ritchlin CT, Bowcock AM, Krueger GG, Lim HW, Weidinger S, Weichenthal M, Voorhees JJ, Rahman P, Gregersen PK, Franke A, Gladman DD, Abecasis GR, Elder JT.

Am J Hum Genet. 2015 Dec 3;97(6):816-36. doi: 10.1016/j.ajhg.2015.10.019. Epub 2015 Nov 28.


Validity of the Simple-Measure for Assessing Psoriasis Activity (S-MAPA) for objectively evaluating disease severity in patients with plaque psoriasis.

Chiesa Fuxench ZC, Callis Duffin K, Siegel M, Van Voorhees AS, Gelfand JM.

J Am Acad Dermatol. 2015 Nov;73(5):868-70. doi: 10.1016/j.jaad.2015.07.001. No abstract available.


Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.

Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L, Papp K, Spelman L, Toth D, Kerdel F, Armstrong AW, Stingl G, Kimball AB, Bachelez H, Wu JJ, Crowley J, Langley RG, Blicharski T, Paul C, Lacour JP, Tyring S, Kircik L, Chimenti S, Callis Duffin K, Bagel J, Koo J, Aras G, Li J, Song W, Milmont CE, Shi Y, Erondu N, Klekotka P, Kotzin B, Nirula A.

N Engl J Med. 2015 Oct;373(14):1318-28. doi: 10.1056/NEJMoa1503824.


Desired Improvement Tool (DIT): A tool to assess desire for improvement in psoriasis patients.

Zaghi D, Weir C, Ying J, Carlin C, Greene T, DeShazo R, Callis Duffin K, Krueger GG.

J Dermatolog Treat. 2016;27(1):27-30. doi: 10.3109/09546634.2015.1050351. Epub 2015 Aug 6.


Onset of psoriatic arthritis during ustekinumab treatment for psoriasis: a case series of seven patients.

Jones BB, Millsop JW, Walsh JA, Krueger GG, Callis Duffin K.

Br J Dermatol. 2015 Jul;173(1):272-4. doi: 10.1111/bjd.13645. Epub 2015 May 18. No abstract available.


Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical setting.

Takeshita J, Wang S, Shin DB, Callis Duffin K, Krueger GG, Kalb RE, Weisman JD, Sperber BR, Stierstorfer MB, Brod BA, Schleicher SM, Robertson AD, Linn KA, Shinohara RT, Troxel AB, Van Voorhees AS, Gelfand JM.

J Am Acad Dermatol. 2014 Dec;71(6):1167-75. doi: 10.1016/j.jaad.2014.08.003. Epub 2014 Sep 24.


Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting.

Takeshita J, Callis Duffin K, Shin DB, Krueger GG, Robertson AD, Troxel AB, Van Voorhees AS, Gelfand JM.

J Am Acad Dermatol. 2014 Oct;71(4):633-41. doi: 10.1016/j.jaad.2014.05.001. Epub 2014 Jun 11.


Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis.

Chung J, Callis Duffin K, Takeshita J, Shin DB, Krueger GG, Robertson AD, Troxel AB, Van Voorhees AS, Edson-Heredia E, Gelfand JM.

J Am Acad Dermatol. 2014 Oct;71(4):623-32. doi: 10.1016/j.jaad.2014.04.063. Epub 2014 Jun 2.


Practice GAPS: preventing and detecting antibodies to anti-tumor necrosis factor agents: gaps in practice or in evidence?

Callis Duffin K.

JAMA Dermatol. 2014 Feb;150(2):136-7. doi: 10.1001/jamadermatol.2013.8375. No abstract available.


Psoriasis and psoriatic arthritis video project: an update from the 2012 GRAPPA annual meeting.

Callis Duffin K, Armstrong AW, Mease PJ.

J Rheumatol. 2013 Aug;40(8):1455-6. doi: 10.3899/jrheum.130463.


Dermatology screening tools: project update from the GRAPPA 2012 annual meeting.

Gladman DD, Helliwell PS, Khraishi M, Callis Duffin K, Mease PJ.

J Rheumatol. 2013 Aug;40(8):1425-7. doi: 10.3899/jrheum.130455.


Outcome measures for psoriasis severity: a report from the GRAPPA 2012 annual meeting.

Callis Duffin K, Gottlieb AB.

J Rheumatol. 2013 Aug;40(8):1423-4. doi: 10.3899/jrheum.130454.


Using Hawthorne effects to improve adherence in clinical practice: lessons from clinical trials--reply.

Gelfand JM, Wang S, Takeshita J, Robertson AD, Krueger GG, Callis Duffin K, Van Voorhees AS.

JAMA Dermatol. 2013 Apr;149(4):491. doi: 10.1001/jamadermatol.2013.2846. No abstract available.


A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.

Lebwohl MG, Kircik L, Callis Duffin K, Pariser D, Hooper M, Wenkert D, Thompson EH, Yang J, Kricorian G, Koo J.

J Am Acad Dermatol. 2013 Sep;69(3):385-92. doi: 10.1016/j.jaad.2013.03.031. Epub 2013 May 1.


Limitations in screening instruments for psoriatic arthritis: a comparison of instruments in patients with psoriasis.

Walsh JA, Callis Duffin K, Krueger GG, Clegg DO.

J Rheumatol. 2013 Mar;40(3):287-93. doi: 10.3899/jrheum.120836. Epub 2013 Feb 1.


Exploring priority research areas in psoriasis and psoriatic arthritis from dermatologists' perspective: a report from the GRAPPA 2011 annual meeting.

Armstrong AW, Callis Duffin K, Garg A, Gelfand JM, Gottlieb AB, Krueger GG, Qureshi AA, Rosen CF.

J Rheumatol. 2012 Nov;39(11):2204-10. doi: 10.3899/jrheum.120825.


Psoriasis and psoriatic arthritis video project: an update from the GRAPPA 2011 annual meeting.

Callis Duffin K, Armstrong AW, Mease PJ.

J Rheumatol. 2012 Nov;39(11):2198-200. doi: 10.3899/jrheum.120823.


Variation in dermatologist beliefs about the safety and effectiveness of treatments for moderate to severe psoriasis.

Abuabara K, Wan J, Troxel AB, Shin DB, Van Voorhees AS, Bebo BF Jr, Krueger GG, Callis Duffin K, Gelfand JM.

J Am Acad Dermatol. 2013 Feb;68(2):262-9. doi: 10.1016/j.jaad.2012.07.007. Epub 2012 Aug 19.


Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis.

Yeung H, Wan J, Van Voorhees AS, Callis Duffin K, Krueger GG, Kalb RE, Weisman JD, Sperber BR, Brod BA, Schleicher SM, Bebo BF Jr, Shin DB, Troxel AB, Gelfand JM.

J Am Acad Dermatol. 2013 Jan;68(1):64-72. doi: 10.1016/j.jaad.2012.06.035. Epub 2012 Jul 28.


The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project).

Helliwell PS, FitzGerald O, Fransen J, Gladman DD, Kreuger GG, Callis-Duffin K, McHugh N, Mease PJ, Strand V, Waxman R, Azevedo VF, Beltran Ostos A, Carneiro S, Cauli A, Espinoza LR, Flynn JA, Hassan N, Healy P, Kerzberg EM, Lee YJ, Lubrano E, Marchesoni A, Marzo-Ortega H, Porru G, Moreta EG, Nash P, Raffayova H, Ranza R, Raychaudhuri SP, Roussou E, Scarpa R, Song YW, Soriano ER, Tak PP, Ujfalussy I, de Vlam K, Walsh JA.

Ann Rheum Dis. 2013 Jun;72(6):986-91. doi: 10.1136/annrheumdis-2012-201341. Epub 2012 Jul 13.


Dermatologist preferences for treatments to compare in future randomized controlled comparative effectiveness trials for moderate to severe psoriasis.

Wan J, Abuabara K, Troxel AB, Shin DB, Van Voorhees AS, Bebo BF Jr, Krueger GG, Callis Duffin K, Gelfand JM.

Arch Dermatol. 2012 Apr;148(4):539-41. doi: 10.1001/archdermatol.2011.1399. No abstract available.


Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting.

Gelfand JM, Wan J, Callis Duffin K, Krueger GG, Kalb RE, Weisman JD, Sperber BR, Stierstorfer MB, Brod BA, Schleicher SM, Bebo BF Jr, Troxel AB, Shin DB, Steinemann JM, Goldfarb J, Yeung H, Van Voorhees AS.

Arch Dermatol. 2012 Apr;148(4):487-94. doi: 10.1001/archdermatol.2012.370.

Supplemental Content

Loading ...
Support Center